Hjem › Glioblastom › Texas
Glioblastom kliniske forsøg i Texas
33 studier for Glioblastom søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University of Texas - MD Anderson Cancer Center, Houston
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT03970447GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
- Baylor St. Luke's Medical Center, Houston
RekruttererFase 1
Alder 21 til 70 · Alle køn · Opdateret 30. sep. 2026 · NCT06815432Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05902169A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05303467A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
RekruttererFase 1/2
Op til 25 år · Alle køn · Opdateret 25. sep. 2026 · NCT04094610MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Baylor Scott & White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT05765812Anti-GD2 ADC M3554 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06641908A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- NEXT Dallas - Oncology Department, Irving
- START | San Antonio, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06914128Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
RekruttererObservationsstudie
12 Months – 39 Years · Alle køn · Opdateret 8. sep. 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
RekruttererFase 1
36 Months – 22 Years · Alle køn · Opdateret 4. sep. 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07579208Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT07733674A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- The University of Texas M. D. Anderson Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 21. jul. 2026 · NCT06672575Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- M D Anderson Cancer Center, Houston
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 20. jul. 2026 · NCT04479696Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT04623931DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UTHealth Houston, Houston
- Baylor College of Medicine, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. jul. 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 1 til 21 · Alle køn · Opdateret 29. jun. 2026 · NCT06333899Imaging Acetadote Metabolism in Glioblastoma
- University of Texas Southwestern Medical Center, Dallas
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 23. jun. 2026 · NCT07387666Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
RekruttererFase 2
12 Months – 39 Years · Alle køn · Opdateret 29. maj 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06810544HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- Houston Methodist Neurological Institute, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT03596086Sacituzumab Govitecan in Recurrent Glioblastoma
- Texas Oncology Austin, Austin
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT04559230HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- Houston Methodist Neurological Institute, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT03603405SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2025 · NCT05941507Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
- Mays Cancer Center, UT Health San Antonio, San Antonio
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 27. aug. 2025 · NCT04863950Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- UT MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. jun. 2025 · NCT05879367Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2025 · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- UT Southwestern Medical Center, Dallas
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 26. mar. 2025 · NCT01906385Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.